Skip to content

Advertisement

Filaria Journal

What do you think about BMC? Take part in

Volume 2 Supplement 1

Report of a Scientific Working Group on Serious Adverse Events following Mectizan treatment of onchocerciasis in Loa loa endemic areas

Reviews

This review is part of a collection of working papers first presented at the Scientific Working Group on Serious Adverse Events following Mectizan treatment of onchocerciasis in Loa loa endemic areas, held between 28 - 30 May 2002 at Shrigley Hall Hotel, Manchester, UK. The meeting was sponsored by the Mectizan® Donation Program, Merck & Co., Inc., and GlaxoSmithKline and and was kindly hosted by the Lymphatic Filariasis Support Centre, Liverpool School of Tropical Medicine.

Manchester, UK28 - 30 May 2002

  1. Content type: Review

    In August 2002, 65 cases of Loa-associated neurological Serious Adverse Events were reported after ivermectin treatment. The first signs, occurring within the 12–24 hours following treatment, included fatigue, ge...

    Authors: Michel Boussinesq, Jacques Gardon, Nathalie Gardon-Wendel and Jean-Philippe Chippaux

    Citation: Filaria Journal 2003 2(Suppl 1):S4

    Published on:

  2. Content type: Review

    Reactions are commonly associated with the chemotherapy of onchocerciasis. However unmanageable reactions are uncommon when ivermectin (Mectizan®) is used for the treatment of this infection, and this drug has pr...

    Authors: Charles D Mackenzie, Timothy G Geary and John A Gerlach

    Citation: Filaria Journal 2003 2(Suppl 1):S5

    Published on:

  3. Content type: Review

    Of the 207 Serious Adverse Events (SAEs) following treatment with Mectizan® (ivermectin, Merck, Sharpe & Dohme) that were reported from 1989 to 2001 through the passive SAE surveillance system required of all onc...

    Authors: Nana AY Twum-Danso

    Citation: Filaria Journal 2003 2(Suppl 1):S7

    Published on:

  4. Content type: Review

    The occurrence of Loa loa encephalopathy following mass treatment of onchocerciasis with Mectizan® has adversely affected onchocerciasis control efforts in central Africa. Persons with very high densities of L. l...

    Authors: David G Addiss, Richard Rheingans, Nana AY Twum-Danso and Frank O Richards

    Citation: Filaria Journal 2003 2(Suppl 1):S9

    Published on:

  5. Content type: Review

    In areas co-endemic for loiasis and onchocerciasis, the classic Community-Directed Treatment using ivermectin (Mectizan®) must be adapted as additional program activities, better communication and tighter control...

    Authors: Nancy J Haselow, Julie Akame, Cyrille Evini and Serge Akongo

    Citation: Filaria Journal 2003 2(Suppl 1):S10

    Published on:

Advertisement